QIACX
Price
$57.35
Change
-$0.12 (-0.21%)
Updated
Jun 2 closing price
Net Assets
3.79B
VTSMX
Price
$182.14
Change
+$0.43 (+0.24%)
Updated
Jun 2 closing price
Net Assets
2.2T
Interact to see
Advertisement

QIACX vs VTSMX

Header iconQIACX vs VTSMX Comparison
Open Charts QIACX vs VTSMXBanner chart's image
QIACX vs VTSMX Comparison Chart in %
View a ticker or compare two or three
VS
QIACX vs. VTSMX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is QIACX is a Hold and VTSMX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VTSMX has more cash in the bank: 2.2T vs. QIACX (3.79B). VTSMX pays higher dividends than QIACX: VTSMX (0.93) vs QIACX (0.24). QIACX was incepted earlier than VTSMX: QIACX (24 years) vs VTSMX (34 years). QIACX (0.92) is less costly to investors than VTSMX (0.06). QIACX is a more actively managed with annual turnover of: 62.00 vs. VTSMX (3.00). VTSMX has a lower initial minimum investment than QIACX: VTSMX (0) vs QIACX (1000000). VTSMX annual gain was more profitable for investors over the last year : 28.26 vs. QIACX (19.39). VTSMX return over 5 years is better than : 72.41 vs. QIACX (42.99).
QIACXVTSMXQIACX / VTSMX
Total Expense Ratio0.750.061,250%
Annual Report Gross Expense Ratio0.920.061,533%
Fund Existence24 years34 years-
Gain YTD8.86511.38478%
Front LoadN/AN/A-
Min. Initial Investment10000000-
Min. Initial Investment IRAN/AN/A-
Net Assets3.79B2.2T0%
Annual Yield % from dividends0.240.9325%
Returns for 1 year19.3928.2669%
Returns for 3 years73.5376.0297%
Returns for 5 years42.9972.4159%
Returns for 10 years184.87259.9971%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NIPG0.400.02
+4.07%
NIP Group Inc
ANGX2.860.07
+2.51%
ANGEL STUDIOS, INC.
J121.94-1.08
-0.88%
Jacobs Solutions
SHFS0.46-0.01
-3.15%
SHF Holdings Inc
ARQT20.79-0.68
-3.17%
Arcutis Biotherapeutics